why choose us

First received: June 05, 2023

Clinical Trial: MK-0616 (Oral PCSK9 Inhibitor) Renal Impairment Study 2 (MK-0616-020)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Hypercholesterolaemia

Study Type: INTERVENTIONAL


Official Title: An Open-Label, Single-Dose Clinical Study to Evaluate the Pharmacokinetics of MK-0616 in Participants With Varying Degrees of Renal Impairment

Brief Summary: The primary objective of the study is to compare the plasma pharmacokinetics (PK) of MK-0616 following a single 20 mg dose in participants on a background of statin therapy with varying degrees of renal impairment (moderate, severe, end stage renal disease [ESRD]) to those of healthy mean matched control participants on a background of statin therapy.There is no formal hypothesis.

Read more